

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No.)*

Cytoclonal Pharmaceuticals Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

23282G 105000
(CUSIP Number)

Richard H. Davimos TTEE
Richard H. Davimos Trust
U/A/D 5/12/92 FBO Richard H. Davimos
450 S.W. 17th Street
Boca Raton, Fl 33432
561-391-3583

Davimos Foundation
450 S.W. 17th Street
Boca Raton, Fl 33432
561-391-1500

Richard H. Davimos in Trust
for Steven A. Davimos
450 S.W. 17th Street
Boca Raton, Fl 33432
561-391-3583

Robert S. Davimos
415 S.W. 17th Street
Boca Raton, Fl 33432
561-361-1116

John L. Davimos
501 Country Valley Road
Westlake Village, Ca 91361
805-496-1777

Richard Davimos Jr.
83 Leonardo Court
West Orange, N.J. 07052
973-669-0843

Marilyn Davimos
450 S.W. 17th Street
Boca Raton, Fl 33432
561-391-3583

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

April 1, 1998
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-l(b)(3) or (4), check the following box ☐.

Check the following box if a fee is being paid with the statement: ☐. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7).

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13a-1(a) for other parties to whom copies should be sent.

The remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1. Name of reporting person; S.S. or I.R.S. identification no. of above person.
Richard H. Davimos TTEE ###-##-####
Davimos Foundation 22-609-2435
Richard H. Davimos in trust for
for Steven A. Davimos ###-##-####
Robert S. Davimos ###-##-####
John L. Davimos 146-44-393967
Richard Davimos Jr. 136-443970
Maralyn Davimos 055-244128
2. Check the appropriate box if a member of a group.* (a) ☐ (b) ☒
3. SEC use only.
4. Source of funds.*
PF, 00
5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e). ☐
6. Citizenship or place of organization.
All U.S. citizens
7. Number of shares beneficially owned by each reporting person with sole voting power.
Richard H. Davimos -- 373,465
Robert S. Davimos -- 49,170
John L. Davimos -- 26,093
Richard Davimos Jr. -- 20,113
Marilyn Davimos -- 12,871
8. Number of shares beneficially owned by each reporting person with shared voting power.
None
9. Number of shares beneficially owned by each reporting person with sole dispositive power.
Richard H. Davimos -- 373,465
Robert S. Davimos -- 49,170
John L. Davimos -- 26,093
Richard Davimos Jr. -- 20,113
Marilyn Davimos -- 12,871
10. Number of shares beneficially owned by each reporting person with shared dispositive power.
None
11. Aggregate amount beneficially owned by each reporting person.
Richard H. Davimos -- 373,465
Robert S. Davimos -- 49,170
John L. Davimos -- 26,093
Richard Davimos Jr. -- 20,113
Marilyn Davimos -- 12,871
12. Check box if the aggregate amount in Row (11) excludes certain shares.*

Excludes 14,999 shares owned by Davimos Foundation and 10,000 shares in trust for Steven A. Davimos in which Mr. Richard H. Davimos has no beneficial interest but has sole dispositive power. Steven Davimos is a beneficial owner but is without any dispositive power.

13. Percent of class presented by amount in Row (11).

Richard H. Davimos	0.0393	Richard Davimos Jr.	0.0021
Robert S. Davimos	0.0051	Marilyn Davimos	0.0014
John L. Davimos	0.0027	Total =	0.0505

14. Type of reporting person.*

*SEE INSTRUCTIONS BEFORE FILLING OUT!

INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7

(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.

Item 1. Security and Issuer

The reporting parties own or control warrants which if exercised would entitle the acquisition of an additional 248,000 shares of the Common Stock.

Each of the reporting persons disclaims beneficial ownership of the shares of Common Stock beneficially owned by any other reporting person.

No reporting person has any present plans or proposals which relate to or would result in any of the actions or events described in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

NAME

DATE

- - - -

/s/ RICHARD H. DAVIMOS

September 18, 1998

Richard H. Davimos TTEE

*

September 18, 1998

Davimos Foundation

*

September 18, 1998

Richard H. Davimos in Trust
For Steven A. Davimos

*

September 18, 1998

Robert S. Davimos

*

September 18, 1998

John L. Davimos

*

September 18, 1998

Richard Davimos Jr.

/s/ MARILYN DAVIMOS

September 18, 1998